Icahn School Of Medicine At Mount Sinai

Date of Award

01.09.2025

Program

Therapeutics

Amount

$1,167,761.00

Term of Grant

24 months

Project Title

Development of Novel LRRK2 Inhibitors to Treat Crohn's Disease

Project Description

There is persistent need to identify and develop novel drugs to induce and maintain remission, heal the damaged tissue, and improve quality of life for Crohn's disease (CD) patients. Mutations in the LRRK2 gene are strongly associated with CD development. This project will repurpose LRRK2 inhibitors approved to treat Parkinson's disease to generate a safe, gut-restricted, oral drug candidate that can protect intestinal function and suppress inflammation.